INmune Bio Sets Global Access for Experimental Therapy
The company partners with Uniphar to facilitate named-patient access to its investigational skin treatment ahead of regulatory filings.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Do you trust that biotech firms are prioritizing patient access as they scale their global infrastructure?
INmune Bio has signed a Master Services Agreement with Uniphar Durbin Ireland Limited to enable named-patient access to its investigational therapy, Ebstrocel. This development provides a pathway for the allogeneic stromal cell therapy, which currently lacks regulatory approval, to reach patients in specific European and MENA markets.
Why it matters
The partnership allows INmune Bio to establish international commercial access for Ebstrocel in a capital-efficient manner without building independent infrastructure in every market. This move prepares the firm for potential commercialization as it works toward formal regulatory submissions.
Uniphar provides logistics and market access across its network of 160 countries and 3,600 staff. The agreement serves as a precursor to pending regulatory applications in the UK and EU, following the established paths of competing therapies Vyjuvek and Zevaskyn.
The players
INmune Bio
A Boca Raton-based biotechnology firm focused on therapies for rare diseases and immune-mediated conditions.
Uniphar Durbin Ireland Limited
A specialized provider of regulatory and commercial services with operations spanning 160 countries.
The details
Ebstrocel is an allogeneic stromal cell therapy—a treatment using donor-derived structural cells—currently under investigation for recessive dystrophic epidermolysis bullosa, a rare genetic skin fragility condition. The agreement with Uniphar leverages their existing regulatory feasibility and order-to-cash infrastructure to facilitate named-patient access, a mechanism allowing access to unauthorized medicines for patients with specific clinical needs.
Timeline
October 21, 2026: INmune Bio and Uniphar sign the Master Services Agreement.
2026: Planned submission of a marketing authorisation application to the UK MHRA.
2027: Planned submission of a marketing authorisation application to the EU EMA.
The Tech Race
This partnership mirrors the commercial strategies of firms like Krystal Biotech and Abeona Therapeutics, which recently secured approvals for their epidermolysis bullosa therapies. By utilizing an established distributor, INmune Bio is attempting to accelerate its footprint against these existing market benchmarks.
Patients with recessive dystrophic epidermolysis bullosa in supported European and MENA regions may gain early access to Ebstrocel through physician-led requests. The clinical availability depends entirely on the completion of pending regulatory milestones and formal authorization from national health bodies.
The takeaway
This deal provides a scalable blueprint for managing international distribution for unapproved therapies. Observers should track the 2026 UK MHRA and 2027 EU EMA marketing authorisation applications as the primary indicators of Ebstrocel's path to full market entry.
Further reading
For broader trends in the industry, visit the Biotech section.
Live Poll
Do you trust that biotech firms are prioritizing patient access as they scale their global infrastructure?
